STOCK TITAN

Palisade Bio (PALI) Financials

PALI NASDAQ
Trailing 12 months to September 30, 2026
Revenue $500K n/m YoY
Net Income -$43.7M n/m YoY
EPS (Diluted) -$0.30 FY2025 annual
Operating Cash Flow -$26.4M n/m YoY
Market Cap $150.7M as of Nov 20, 2026
Price / Sales 301x on $500K revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 1.3x on $112.4M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PALI SEC filings page.

Palisade Bio, Inc. (PALI) reported $500K in revenue over the twelve months to Sep 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PALI FY2025

Palisade remains a development-stage business whose FY2025 balance-sheet expansion came from financing while operations continued consuming cash.

FY2025 financing cash flow was $134.4M against operating cash flow of -$10.8M. Assets expanded 1134.8%, indicating that the enlarged balance sheet reflects funding activity more than internally generated operating scale.

The cash-conversion picture is not a mirror of the reported loss: FY2025 net loss was $16.8M while operating cash flow was -$10.8M, so the cash drain was smaller than the accounting loss. That gap does not make operations self-funding; financing remained necessary to support the business.

FY2025 liabilities were only 3.7% of assets, while return on assets was -12.5%; the enlarged capital base is lightly obligated but has not yet translated into earnings. Spending also shifted toward administration: R&D fell 36.3% while SG&A rose 35.7%, a resource-allocation change rather than evidence of operating leverage.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Palisade Bio, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
3/7

Palisade Bio, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing
N/A

Palisade Bio, Inc. reported a net loss of $16.8M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Palisade Bio, Inc. reported an operating loss of $18.1M against $10K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$0
YoYn/m
QoQ-100.0%

Palisade Bio, Inc. generated $0 in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 100.0%.

EBITDA
-$15.7M
YoYn/m
QoQn/m
5Y CAGRn/m

Palisade Bio, Inc.'s EBITDA was -$15.7M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$14.6M
YoYn/m
QoQn/m

Palisade Bio, Inc. reported a net loss of $14.6M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.07
QoQn/m

Palisade Bio, Inc. earned -$0.07 per diluted share (EPS) in Q3 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Cash & Debt
$113.6M
YoY+2073.6%
QoQ-9.2%
5Y CAGR+51.8%

Palisade Bio, Inc. held $113.6M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
179M
QoQ+2.9%

Palisade Bio, Inc. had 179M shares outstanding in Q3 2026. Against the prior quarter it is up 2.9%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-13.0%
YoY+76.3pp
QoQ-4.3pp
5Y change-219.3pp

Palisade Bio, Inc.'s quarterly ROE was -13.0% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 76.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.3 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$12.0M
YoY+760.8%
QoQ+62.2%

Palisade Bio, Inc. invested $12.0M in research and development in Q3 2026. This represents an increase of 760.8% from the same quarter a year earlier. Against the prior quarter it is up 62.2%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

PALI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PALI quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$0n/m$500Kn/m$0n/m$0n/m$0n/m$0n/m$0n/m$0
R&D Expenses$12.0M+760.8%$7.4M+341.8%$6.4M+573.4%$6.2M$1.4M-91.3%$1.7M-36.3%$950K-57.1%N/A
SG&A Expenses$5.1M+235.1%$4.8M+310.8%$4.4M+219.9%$3.8M+193.4%$1.5M+4.9%$1.2M-26.2%$1.4M-6.8%$1.3M-16.7%
Operating Income-$15.7Mn/m-$11.7Mn/m-$10.7Mn/m-$10.0Mn/m-$2.9Mn/m-$2.8Mn/m-$2.3Mn/m-$3.4Mn/m
EBITDA-$15.7Mn/m-$11.7Mn/m-$10.7Mn/m-$10.0Mn/m-$2.9Mn/m-$2.8Mn/m-$2.3Mn/m-$3.4Mn/m
Interest Expense$0-100.0%$0-100.0%$1K0.0%$2K-33.3%$5K-16.7%$2K0.0%$1K0.0%$3K-25.0%
Net Income-$14.6Mn/m-$10.6Mn/m-$9.6Mn/m-$8.9Mn/m-$2.9Mn/m-$2.8Mn/m-$2.2Mn/m-$3.3Mn/m
EPS (Basic)-$0.07-$0.05-$0.05N/A-$0.38-$0.58-$0.47-$0.69
EPS (Diluted)-$0.07-$0.05-$0.05N/A-$0.38-$0.58-$0.47-$0.69
Diluted Shares (Avg)212M211M210MN/A7M5M5MN/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

PALI Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PALI quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'25FilingQ4'2410-K
Total Assets$118.5M+1600.1%$127.3M+1809.6%$133.3M+1527.8%$134.3M+1134.8%$7.0M-25.3%$6.7M-48.2%$8.2M-35.3%$10.9M-22.6%
Current Assets$117.5M+1620.5%$127.3M+1873.9%$133.2M+1589.4%$134.2M+1179.0%$6.8M-23.0%$6.4M-47.6%$7.9M-34.3%$10.5M-21.3%
Cash & Equivalents$113.6M+2073.6%$125.2M+2210.7%$132.6M+1734.4%$133.4M+1258.2%$5.2M-35.0%$5.4M-52.3%$7.2M-35.9%$9.8M-21.0%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Accounts ReceivableN/A$500Kn/mN/A$0n/mN/A$0N/A$0
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$6.1M+62.3%$5.6M+37.6%$6.0M+108.2%$5.0M+46.5%$3.8M+37.9%$4.0M+38.5%$2.9M+10.5%$3.4M+23.7%
Current Liabilities$5.8M+67.5%$5.2M+32.1%$5.6M+102.4%$4.6M+43.3%$3.5M+29.7%$4.0M+40.0%$2.8M+12.6%$3.2M+25.1%
Non-Current Liabilities$279K-1.4%$321K+316.9%$333K+306.1%$328K+115.8%$283K+502.1%$77K-10.5%$82K-32.2%$152K-0.7%
Total Equity$112.4M+3400.6%$121.7M+4546.9%$127.4M+2289.1%$129.4M+1626.9%$3.2M-51.4%$2.6M-73.7%$5.3M-47.0%$7.5M-33.8%
Retained EarningsN/AN/AN/AN/AN/A$141.0Mn/m$138.2Mn/m$135.9M+11.9%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

PALI Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PALI quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$11.8Mn/m-$7.6Mn/m-$3.9Mn/m-$3.1Mn/m-$3.6Mn/m-$1.8Mn/m-$2.3Mn/m-$2.4Mn/m
Depreciation & Amortization$0-100.0%$0-100.0%$0-100.0%$0n/m$1K0.0%$1K0.0%$1K0.0%$0n/m
Stock-Based Compensation$5.1M+5842.4%$4.8M+7858.3%$4.3M+6127.5%N/A$85K-7.6%$60K-83.2%$69K-41.5%N/A
Capital ExpendituresN/AN/AN/AN/AN/AN/AN/A$0n/m
Free Cash FlowN/AN/AN/AN/AN/AN/AN/A-$2.4Mn/m
Investing Cash FlowN/AN/AN/AN/AN/AN/AN/A$0n/m
Financing Cash Flow$200K-94.1%$147K+3575.0%$3.1Mn/m$131.3M+3055.5%$3.4Mn/m$4K-99.9%-$258K-112.7%$4.2Mn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PALI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PALI quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating MarginN/A-2339.6%N/AN/AN/AN/AN/AN/A
Net MarginN/A-2114.8%N/AN/AN/AN/AN/AN/A
Return on Equity-13.0%+76.3pp-8.7%+97.6pp-7.5%+34.3pp-6.9%+37.7pp-89.3%-36.5pp-106.3%-65.3pp-41.8%-6.8pp-44.6%-18.4pp
Return on Assets-12.3%+28.8pp-8.3%+33.5pp-7.2%+20.0pp-6.6%+24.1pp-41.1%-3.8pp-41.8%-10.1pp-27.2%+0.7pp-30.7%-9.6pp
Current Ratio20.16+18.2x24.26+22.6x23.71+20.9x28.95+25.7x1.96-1.3x1.62-2.7x2.84-2.0x3.24-1.9x
Liabilities-to-Equity0.05-1.1x0.05-1.5x0.05-0.5x0.04-0.4x1.17+0.8x1.54+1.3x0.54+0.3x0.45+0.2x
Asset Turnover0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x0.00

Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Palisade Bio, Inc. PALI FY2025 $0 -$16.8M N/A $150.7M —
Oramed Pharmaceuticals Inc. ORMP FY2025 $2.0M $64.0M N/A $155.2M 53/100
InflaRx N.V. IFRX FY2025 $34K -$53.6M N/A $153.3M —
ProQR Therapeutics N.V. PRQR FY2025 $18.7M -$49.5M N/A $147.0M 74/100
BridgeBio Oncology Therapeutics, Inc. BBOT FY2025 N/A -$134.0M N/A $145.3M —
Sutro Biopharma, Inc. STRO FY2025 $102.5M -$191.1M N/A $142.8M 42/100

Frequently Asked Questions

Palisade Bio, Inc. (PALI) reported $0 in total revenue for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

No, Palisade Bio, Inc. (PALI) reported a net loss of $43.7M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $16.8M.

Palisade Bio, Inc. (PALI) reported diluted earnings per share of -$0.30 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Palisade Bio, Inc. (PALI) had EBITDA of -$18.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Palisade Bio, Inc. (PALI) has a return on equity of -13.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Palisade Bio, Inc. (PALI) recorded an outflow of $10.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Palisade Bio, Inc. (PALI) had $134.3M in total assets as of fiscal year 2025, including both current and long-term assets.

Palisade Bio, Inc. (PALI) invested $10.2M in research and development during fiscal year 2025.

Palisade Bio, Inc. (PALI) had 166M shares outstanding as of fiscal year 2025.

Palisade Bio, Inc. (PALI) had a current ratio of 28.95 as of fiscal year 2025, which is generally considered healthy.

Palisade Bio, Inc. (PALI) had a liabilities-to-equity ratio of 0.04 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Palisade Bio, Inc. (PALI) had a return on assets of -12.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Palisade Bio, Inc. (PALI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $150.7M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Palisade Bio, Inc. (PALI) trades at 301x sales, its market capitalization divided by $500K revenue, trailing 12 months to September 30, 2026. The market capitalization is $150.7M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Palisade Bio, Inc. (PALI) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Palisade Bio, Inc. (PALI) reported a net loss of $16.8M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Palisade Bio, Inc. (PALI) reported an operating loss of $18.1M against $10K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top